01
Jun

Bristol-Myers Squibb is the leader right now in immuno-oncology and checkpoint inhibitors and it clearly is willing to get aggressive about defending that early edge. In a move that shows just how competitive this blockbuster field has become, the big biotech wants to force one of its ex-R&D leaders in I/O to sit out the next year rather than go to work for a major league rival.

…read more

Source: Bristol-Myers fires off a lawsuit to sideline R&D defector headed to rival AstraZeneca

    

0 No comments